Epigenetic alterations and microRNAs

References

• Waddington CH. Preliminary Notes on the Development of the Wings in Normal and Mutant Strains of Drosophila. Proc Natl Acad Sci U S A 1939; 25:299 - 307; http://dx.doi.org/10.1073/pnas.25.7.299; PMID: 16577903
   PubMedGoogle Scholar
• Holliday R. The inheritance of epigenetic defects. Science 1987; 238:163 - 70; http://dx.doi.org/10.1126/science.3310230; PMID: 3310230
   PubMed Web of Science ®Google Scholar
• Bird A. Perceptions of epigenetics. Nature 2007; 447:396 - 8; http://dx.doi.org/10.1038/nature05913; PMID: 17522671
   PubMed Web of Science ®Google Scholar
• Stintzing S, Kemmerling R, Kiesslich T, Alinger B, Ocker M, Neureiter D. Myelodysplastic syndrome and histone deacetylase inhibitors: “to be or not to be acetylated”?. J Biomed Biotechnol 2011; 2011:214143; http://dx.doi.org/10.1155/2011/214143; PMID: 21629744
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007; 128:669 - 81; http://dx.doi.org/10.1016/j.cell.2007.01.033; PMID: 17320505
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042 - 54; http://dx.doi.org/10.1056/NEJMra023075; PMID: 14627790
   PubMed Web of Science ®Google Scholar
• Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39:457 - 66; http://dx.doi.org/10.1038/ng1990; PMID: 17334365
   PubMed Web of Science ®Google Scholar
• Ballestar E, Esteller M. Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger. Biochem Cell Biol 2005; 83:374 - 84; http://dx.doi.org/10.1139/o05-035; PMID: 15959563
   PubMed Web of Science ®Google Scholar
• Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006; 76:23 - 32; http://dx.doi.org/10.1111/j.1600-0609.2005.00559.x; PMID: 16343268
   PubMed Web of Science ®Google Scholar
• Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2003; 17:1813 - 9; http://dx.doi.org/10.1038/sj.leu.2403054
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114:3448 - 58; http://dx.doi.org/10.1182/blood-2009-01-200519; PMID: 19652201
   PubMed Web of Science ®Google Scholar
• Cechova H, Lassuthova P, Novakova L, Belickova M, Stemberkova R, Jencik J, et al. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia. Neoplasma 2012; 59:168 - 74; http://dx.doi.org/10.4149/neo_2012_022; PMID: 22248274
   PubMed Web of Science ®Google Scholar
• Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem 2011; 286:25211 - 23; http://dx.doi.org/10.1074/jbc.M111.235028; PMID: 21532034
   PubMed Web of Science ®Google Scholar
• Fan R, Zhang LY, Wang H, Yang B, Han T, Zhao XL, et al. Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome. Tohoku J Exp Med 2012; 227:119 - 28; http://dx.doi.org/10.1620/tjem.227.119; PMID: 22706399
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang Q, Xu F, Chang C, Li X. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome. Eur J Haematol 2012; 89:469 - 77; http://dx.doi.org/10.1111/ejh.12014; PMID: 23005040
   PubMed Web of Science ®Google Scholar
• Ewalt M, Galili NG, Mumtaz M, Churchill M, Rivera S, Borot F, et al. DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. Blood Cancer J 2011; 1:e9; http://dx.doi.org/10.1038/bcj.2011.7; PMID: 22829128
   PubMedGoogle Scholar
• Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2011; 25:1153 - 8; http://dx.doi.org/10.1038/leu.2011.44
   PubMed Web of Science ®Google Scholar
• Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood 2009; 113:6403 - 10; http://dx.doi.org/10.1182/blood-2009-02-205690; PMID: 19372255
   PubMed Web of Science ®Google Scholar
• Masala E, Valencia A, Buchi F, Nosi D, Spinelli E, Gozzini A, et al. Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. Leuk Res 2012; 36:1290 - 5; http://dx.doi.org/10.1016/j.leukres.2012.05.023; PMID: 22742816
   PubMed Web of Science ®Google Scholar
• Hopfer O, Nolte F, Mossner M, Komor M, Kmetsch A, Benslasfer O, et al. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis. Eur J Haematol 2012; 88:144 - 53; http://dx.doi.org/10.1111/j.1600-0609.2011.01715.x; PMID: 21967505
   PubMed Web of Science ®Google Scholar
• Zhao Y, Gu S, Guo J, Zhang Z, Zhang X, Li X, et al. Aberration of p73 promoter methylation in de novo myelodysplastic syndrome. Hematology 2012; 17:275 - 82; http://dx.doi.org/10.1179/1607845412Y.0000000018; PMID: 22971533
   PubMed Web of Science ®Google Scholar
• Graubert T, Walter MJ. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program 2011; 2011:543 - 9; http://dx.doi.org/10.1182/asheducation-2011.1.543; PMID: 22160087
   PubMedGoogle Scholar
• Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424 - 33; http://dx.doi.org/10.1056/NEJMoa1005143; PMID: 21067377
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29:3723 - 31; http://dx.doi.org/10.1038/onc.2010.117; PMID: 20400977
   PubMed Web of Science ®Google Scholar
• Thol F, Winschel C, Lüdeking A, Yun H, Friesen I, Damm F, et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 2011; 96:1870 - 3; http://dx.doi.org/10.3324/haematol.2011.045559; PMID: 21880636
   PubMed Web of Science ®Google Scholar
• Länger F, Dingemann J, Kreipe H, Lehmann U. Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 2005; 29:325 - 9; http://dx.doi.org/10.1016/j.leukres.2004.08.004; PMID: 15661269
   PubMed Web of Science ®Google Scholar
• Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289 - 301; http://dx.doi.org/10.1056/NEJMoa0810069; PMID: 19474426
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41:838 - 42; http://dx.doi.org/10.1038/ng.391; PMID: 19483684
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, et al, Groupe Francophone des Myélodysplasies. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114:3285 - 91; http://dx.doi.org/10.1182/blood-2009-04-215814; PMID: 19666869
   PubMed Web of Science ®Google Scholar
• Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009; 27:4002 - 6; http://dx.doi.org/10.1200/JCO.2009.22.6985; PMID: 19528370
   PubMed Web of Science ®Google Scholar
• Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468:839 - 43; http://dx.doi.org/10.1038/nature09586; PMID: 21057493
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2011; 25:1147 - 52; http://dx.doi.org/10.1038/leu.2011.71
   PubMed Web of Science ®Google Scholar
• Wang J, Ai X, Gale RP, Xu Z, Qin T, Fang L, et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 2013; 37:305 - 11; PMID: 23099237
   PubMed Web of Science ®Google Scholar
• Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116:3923 - 32; http://dx.doi.org/10.1182/blood-2010-03-274704; PMID: 20693430
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058 - 66; http://dx.doi.org/10.1056/NEJMoa0903840; PMID: 19657110
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324:261 - 5; http://dx.doi.org/10.1126/science.1170944; PMID: 19359588
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739 - 44; http://dx.doi.org/10.1038/nature08617; PMID: 19935646
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2010; 24:1094 - 6; http://dx.doi.org/10.1038/leu.2010.52
   PubMed Web of Science ®Google Scholar
• Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 2010; 95:1668 - 74; http://dx.doi.org/10.3324/haematol.2010.025494; PMID: 20494930
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Kato M, Kawahata R, Matsubara A, Takita J, et al. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2011; 25:184 - 6; http://dx.doi.org/10.1038/leu.2010.241
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2012; 26:101 - 5; http://dx.doi.org/10.1038/leu.2011.298
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553 - 67; http://dx.doi.org/10.1016/j.ccr.2010.11.015; PMID: 21130701
   PubMed Web of Science ®Google Scholar
• Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010; 34:148 - 53; http://dx.doi.org/10.1016/j.leukres.2009.06.019; PMID: 19595458
   PubMed Web of Science ®Google Scholar
• Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009; 10:295 - 304; http://dx.doi.org/10.1038/nrg2540; PMID: 19308066
   PubMed Web of Science ®Google Scholar
• Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42:722 - 6; http://dx.doi.org/10.1038/ng.621; PMID: 20601953
   PubMed Web of Science ®Google Scholar
• Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012; 120:1107 - 17; http://dx.doi.org/10.1182/blood-2011-11-394932; PMID: 22677129
   PubMed Web of Science ®Google Scholar
• Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia: official journal of the Leukemia Society of America. Leukemia Research Fund, UK 2010; 24:1799 - 804; http://dx.doi.org/10.1038/leu.2010.167
   PubMed Web of Science ®Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tönnissen ER, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42:665 - 7; http://dx.doi.org/10.1038/ng.620; PMID: 20601954
   PubMed Web of Science ®Google Scholar
• Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012; 3:623; http://dx.doi.org/10.1038/ncomms1623; PMID: 22233633
   PubMed Web of Science ®Google Scholar
• Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004; 23:4061 - 71; http://dx.doi.org/10.1038/sj.emboj.7600402; PMID: 15385962
   PubMed Web of Science ®Google Scholar
• Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119:1208 - 13; http://dx.doi.org/10.1182/blood-2011-07-367243; PMID: 22053108
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012; 5:12; http://dx.doi.org/10.1186/1756-8722-5-12; PMID: 22436456
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012; 22:180 - 93; http://dx.doi.org/10.1016/j.ccr.2012.06.032; PMID: 22897849
   PubMed Web of Science ®Google Scholar
• Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29:2499 - 506; http://dx.doi.org/10.1200/JCO.2010.33.4938; PMID: 21576631
   PubMed Web of Science ®Google Scholar
• Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12:599 - 612; http://dx.doi.org/10.1038/nrc3343; PMID: 22898539
   PubMed Web of Science ®Google Scholar
• Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006; 107:305 - 8; http://dx.doi.org/10.1182/blood-2005-06-2393; PMID: 16160010
   PubMed Web of Science ®Google Scholar
• Xu F, Yang R, Wu L, He Q, Zhang Z, Zhang Q, et al. Overexpression of BMI1 confers clonal cells resistance to apoptosis and contributes to adverse prognosis in myelodysplastic syndrome. Cancer Lett 2012; 317:33 - 40; http://dx.doi.org/10.1016/j.canlet.2011.11.012; PMID: 22120066
   PubMed Web of Science ®Google Scholar
• Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y, et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011; 90:643 - 53; http://dx.doi.org/10.1007/s00277-010-1128-5; PMID: 21125401
   PubMed Web of Science ®Google Scholar
• Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010; 10:401; http://dx.doi.org/10.1186/1471-2407-10-401; PMID: 20678218
   PubMed Web of Science ®Google Scholar
• Gibbons RJ, Pellagatti A, Garrick D, Wood WG, Malik N, Ayyub H, et al. Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet 2003; 34:446 - 9; http://dx.doi.org/10.1038/ng1213; PMID: 12858175
   PubMed Web of Science ®Google Scholar
• Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004; 10:1957 - 66; http://dx.doi.org/10.1261/rna.7135204; PMID: 15525708
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23:4051 - 60; http://dx.doi.org/10.1038/sj.emboj.7600385; PMID: 15372072
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003; 425:415 - 9; http://dx.doi.org/10.1038/nature01957; PMID: 14508493
   PubMed Web of Science ®Google Scholar
• Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432:231 - 5; http://dx.doi.org/10.1038/nature03049; PMID: 15531879
   PubMed Web of Science ®Google Scholar
• Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432:235 - 40; http://dx.doi.org/10.1038/nature03120; PMID: 15531877
   PubMed Web of Science ®Google Scholar
• Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004; 18:3016 - 27; http://dx.doi.org/10.1101/gad.1262504; PMID: 15574589
   PubMed Web of Science ®Google Scholar
• Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha, the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids Res 2006; 34:4622 - 9; http://dx.doi.org/10.1093/nar/gkl458; PMID: 16963499
   PubMed Web of Science ®Google Scholar
• Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17:3011 - 6; http://dx.doi.org/10.1101/gad.1158803; PMID: 14681208
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281 - 97; http://dx.doi.org/10.1016/S0092-8674(04)00045-5; PMID: 14744438
   PubMed Web of Science ®Google Scholar
• Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN. The role of PACT in the RNA silencing pathway. EMBO J 2006; 25:522 - 32; http://dx.doi.org/10.1038/sj.emboj.7600942; PMID: 16424907
   PubMed Web of Science ®Google Scholar
• Saito K, Ishizuka A, Siomi H, Siomi MC. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in Drosophila cells. PLoS Biol 2005; 3:e235; http://dx.doi.org/10.1371/journal.pbio.0030235; PMID: 15918769
   PubMed Web of Science ®Google Scholar
• Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003; 115:209 - 16; http://dx.doi.org/10.1016/S0092-8674(03)00801-8; PMID: 14567918
   PubMed Web of Science ®Google Scholar
• Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115:199 - 208; http://dx.doi.org/10.1016/S0092-8674(03)00759-1; PMID: 14567917
   PubMed Web of Science ®Google Scholar
• Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proc Natl Acad Sci U S A 2007; 104:9667 - 72; http://dx.doi.org/10.1073/pnas.0703820104; PMID: 17535905
   PubMed Web of Science ®Google Scholar
• Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010; 84:1 - 16; http://dx.doi.org/10.1111/j.1600-0609.2009.01348.x; PMID: 19744129
   PubMed Web of Science ®Google Scholar
• Erdogan B, Facey C, Qualtieri J, Tedesco J, Rinker E, Isett RB, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011; 39:915 - 26, e2; http://dx.doi.org/10.1016/j.exphem.2011.06.002; PMID: 21703983
   PubMed Web of Science ®Google Scholar
• Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011; 4:1; http://dx.doi.org/10.1186/1756-8722-4-1; PMID: 21211043
   PubMed Web of Science ®Google Scholar
• Hussein K, Theophile K, Büsche G, Schlegelberger B, Göhring G, Kreipe H, et al. Significant inverse correlation of microRNA-150/MYB and microRNA-222/p27 in myelodysplastic syndrome. Leuk Res 2010; 34:328 - 34; http://dx.doi.org/10.1016/j.leukres.2009.06.014; PMID: 19615744
   PubMed Web of Science ®Google Scholar
• Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011; 19:313 - 9; http://dx.doi.org/10.1038/ejhg.2010.209; PMID: 21150891
   PubMed Web of Science ®Google Scholar
• Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009; 50:1854 - 9; http://dx.doi.org/10.3109/10428190903147645; PMID: 19883312
   PubMed Web of Science ®Google Scholar
• Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood 2013; 121:2875 - 81; http://dx.doi.org/10.1182/blood-2011-12-397067; PMID: 23390194
   PubMed Web of Science ®Google Scholar
• Rhyasen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 2012; 26:13 - 22; PMID: 21852786
   PubMed Web of Science ®Google Scholar
• Hussein K, Theophile K, Büsche G, Schlegelberger B, Göhring G, Kreipe H, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010; 34:1169 - 74; http://dx.doi.org/10.1016/j.leukres.2010.04.012; PMID: 20627384
   PubMed Web of Science ®Google Scholar
• Vasilatou D, Papageorgiou SG, Kontsioti F, Kontos CK, Tsiotra P, Mpakou V, et al. Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes. Leuk Res 2013; 37:251 - 8; PMID: 23246221
   PubMed Web of Science ®Google Scholar
• Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011; 153:24 - 32; http://dx.doi.org/10.1111/j.1365-2141.2011.08581.x; PMID: 21332710
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104:15805 - 10; http://dx.doi.org/10.1073/pnas.0707628104; PMID: 17890317
   PubMed Web of Science ®Google Scholar
• Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114:5331 - 41; http://dx.doi.org/10.1182/blood-2009-03-211938; PMID: 19850741
   PubMed Web of Science ®Google Scholar
• Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123:819 - 31; http://dx.doi.org/10.1016/j.cell.2005.09.023; PMID: 16325577
   PubMed Web of Science ®Google Scholar
• Zardo G, Ciolfi A, Vian L, Starnes LM, Billi M, Racanicchi S, et al. Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood 2012; 119:4034 - 46; http://dx.doi.org/10.1182/blood-2011-08-371344; PMID: 22327224
   PubMed Web of Science ®Google Scholar
• Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007; 12:457 - 66; http://dx.doi.org/10.1016/j.ccr.2007.09.020; PMID: 17996649
   PubMed Web of Science ®Google Scholar
• Santamaría C, Muntión S, Rosón B, Blanco B, López-Villar O, Carrancio S, et al. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 2012; 97:1218 - 24; http://dx.doi.org/10.3324/haematol.2011.054437; PMID: 22371183
   PubMed Web of Science ®Google Scholar
• Castoro RJ, Saraf AJ, Watanabe Y, Chung W, Adhab SE, Jelinek J, et al. Microrna 124 and Its Role in Response to Epigenetic Therapy in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. blood(ASH Annual Meeting Abstracts)2008; 112.
   Google Scholar
• Xia Q, Hu J, Meng YS. [Abnormal expression of microRNA-124 in patients with leukemia or myelodysplastic syndrome and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012; 20:358 - 61; PMID: 22541098
   PubMedGoogle Scholar
• Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F, et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci U S A 2010; 107:9783 - 8; http://dx.doi.org/10.1073/pnas.1004297107; PMID: 20448201
   PubMed Web of Science ®Google Scholar
• Li X, Xu F, Chang C, Byon J, Papayannopoulou T, Deeg HJ, et al. Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica 2013; 98:414 - 9; PMID: 22983574
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al, International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223 - 32; http://dx.doi.org/10.1016/S1470-2045(09)70003-8; PMID: 19230772
   PubMed Web of Science ®Google Scholar
• Tuma RS. Epigenetic therapies move into new territory, but how exactly do they work?. J Natl Cancer Inst 2009; 101:1300 - 1; http://dx.doi.org/10.1093/jnci/djp342; PMID: 19755677
   PubMed Web of Science ®Google Scholar
• Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004; 101:1241 - 6; http://dx.doi.org/10.1073/pnas.0307708100; PMID: 14734806
   PubMed Web of Science ®Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97:10014 - 9; http://dx.doi.org/10.1073/pnas.180316197; PMID: 10954755
   PubMed Web of Science ®Google Scholar
• Cashen A, Juckett M, Jumonville A, Litzow M, Flynn PJ, Eckardt J, et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol 2012; 91:33 - 8; http://dx.doi.org/10.1007/s00277-011-1240-1; PMID: 21538061
   PubMed Web of Science ®Google Scholar
• Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20:6969 - 78; http://dx.doi.org/10.1093/emboj/20.24.6969; PMID: 11742974
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276:36734 - 41; http://dx.doi.org/10.1074/jbc.M101287200; PMID: 11473107
   PubMed Web of Science ®Google Scholar